INTRODUCTION: Acute cellular rejection (ACR) post-liver transplantation (LT) can usually be reversed with pulse dose steroids. Anti-thymocyte globulin (ATG) is used to treat steroid-resistant rejection (SRR). PATIENTS AND METHODS: We report 15 male and five female LT recipients with a median age of 48.3 (range 14.3-71.7) years, who received ATG for biopsy-proven steroid-resistant rejection (n =13), severe rejection (6), and severe rejection/recurrent autoimmune hepatitis (n = 1) median 42 (range 6-2,456) days following LT. RESULTS: Underlying liver diseases included HCV (n = 7), alcoholic cirrhosis (n = 3), NASH (n = 2), HBV (n = 2), autoimmune hepatitis (n =1), PSC (n = 1), miscellaneous (n = 4) including three re LTs. All patients responded to treatment (median AST declined from 172 to 34U/l, median total bilirubin from 9.1 to 1.3 mg/dl; p < 0.001). Three patients developed recurrent ACR, and none chronic rejection. All HCV patients developed recurrence with significant rises in HCV RNA levels. Infections included pneumonia, sepsis, intraabdominal infection, chronic diarrhea, wound infection, EBV, and CMV disease. After a median follow-up of 65.5 (range 4.3-101.7) months post-ATG and median 67.7 (range 9.3-306.3) months post-LT, 17 patients are alive, two died from sepsis/multi-organ failure and one from HCV recurrence. CONCLUSION: ATG effectively reversed severe and SSR; HCV recurrence and infections remain significant complications.
INTRODUCTION: Acute cellular rejection (ACR) post-liver transplantation (LT) can usually be reversed with pulse dose steroids. Anti-thymocyte globulin (ATG) is used to treat steroid-resistant rejection (SRR). PATIENTS AND METHODS: We report 15 male and five female LT recipients with a median age of 48.3 (range 14.3-71.7) years, who received ATG for biopsy-proven steroid-resistant rejection (n =13), severe rejection (6), and severe rejection/recurrent autoimmune hepatitis (n = 1) median 42 (range 6-2,456) days following LT. RESULTS: Underlying liver diseases included HCV (n = 7), alcoholic cirrhosis (n = 3), NASH (n = 2), HBV (n = 2), autoimmune hepatitis (n =1), PSC (n = 1), miscellaneous (n = 4) including three re LTs. All patients responded to treatment (median AST declined from 172 to 34U/l, median total bilirubin from 9.1 to 1.3 mg/dl; p < 0.001). Three patients developed recurrent ACR, and none chronic rejection. All HCV patients developed recurrence with significant rises in HCV RNA levels. Infections included pneumonia, sepsis, intraabdominal infection, chronic diarrhea, wound infection, EBV, and CMV disease. After a median follow-up of 65.5 (range 4.3-101.7) months post-ATG and median 67.7 (range 9.3-306.3) months post-LT, 17 patients are alive, two died from sepsis/multi-organ failure and one from HCV recurrence. CONCLUSION: ATG effectively reversed severe and SSR; HCV recurrence and infections remain significant complications.
Authors: A Demetris; D Adams; C Bellamy; K Blakolmer; A Clouston; A P Dhillon; J Fung; A Gouw; B Gustafsson; H Haga; D Harrison; J Hart; S Hubscher; R Jaffe; U Khettry; C Lassman; K Lewin; O Martinez; Y Nakazawa; D Neil; O Pappo; M Parizhskaya; P Randhawa; S Rasoul-Rockenschaub; F Reinholt; M Reynes; M Robert; A Tsamandas; I Wanless; R Wiesner; A Wernerson; F Wrba; J Wyatt; H Yamabe Journal: Hepatology Date: 2000-03 Impact factor: 17.425
Authors: Dixon B Kaufman; Ron Shapiro; Michael R Lucey; Wida S Cherikh; Rami T Bustami; David B Dyke Journal: Am J Transplant Date: 2004 Impact factor: 8.086
Authors: D W Orr; B C Portmann; A S Knisely; S Stoll; M Rela; P Muiesan; M J Bowles; N D Heaton; J G O'Grady; M A Heneghan Journal: Transplant Proc Date: 2005-12 Impact factor: 1.066
Authors: Carlo B Ramirez; Cataldo Doria; Fabrizio di Francesco; Maurizio Iaria; Yoogoo Kang; Ignazio R Marino Journal: J Surg Res Date: 2007-02-08 Impact factor: 2.192
Authors: C G Bijleveld; I J Klompmaker; A P van den Berg; A S Gouw; B G Hepkema; E B Haagsma; R Verwer; M J Slooff Journal: Transpl Int Date: 1996 Impact factor: 3.782
Authors: Nimer Assy; Paul C Adams; Paul Myers; Verra Simon; Gerry Y Minuk; William Wall; Cameron N Ghent Journal: Transplantation Date: 2007-06-27 Impact factor: 4.939
Authors: Jae Geun Lee; Juhan Lee; Jung Jun Lee; Seung Hwan Song; Man Ki Ju; Gi Hong Choi; Myoung Soo Kim; Jin Sub Choi; Soon Il Kim; Dong Jin Joo Journal: Medicine (Baltimore) Date: 2016-06 Impact factor: 1.889
Authors: Dimitri Gassmann; Stefan Weiler; Joachim C Mertens; Cäcilia S Reiner; Bart Vrugt; Mirjam Nägeli; Joanna Mangana; Beat Müllhaupt; Fabienne Jenni; Benjamin Misselwitz Journal: Transplant Direct Date: 2018-07-20